Synnovation Therapeutics
Liangxing Wu's work experience includes serving as the Senior Vice President at Synnovation Therapeutics since September 2021. Prior to that, they worked as the Executive Director at Incyte from November 2011 to July 2021. Additionally, they worked as a Postdoc at UC Berkeley from September 2009 to November 2011.
Liangxing Wu holds a PhD in Organic Chemistry, which they obtained from Texas A&M University between the years 2003 and 2009. Prior to that, they earned a Bachelor of Science degree in Chemistry from the University of Science and Technology of China, where they studied from 1999 to 2003.
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.